JP2019529906A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529906A5 JP2019529906A5 JP2019514252A JP2019514252A JP2019529906A5 JP 2019529906 A5 JP2019529906 A5 JP 2019529906A5 JP 2019514252 A JP2019514252 A JP 2019514252A JP 2019514252 A JP2019514252 A JP 2019514252A JP 2019529906 A5 JP2019529906 A5 JP 2019529906A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- subject
- biomarkers
- inhibitor
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 16
- 239000000090 biomarker Substances 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 206010019860 Hereditary angioedema Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004899 14-3-3 Proteins Human genes 0.000 claims 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims 2
- 108010058432 Chaperonin 60 Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 101000818893 Homo sapiens 14-3-3 protein beta/alpha Proteins 0.000 claims 2
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 claims 2
- 108700012928 MAPK14 Proteins 0.000 claims 2
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims 2
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 2
- 102100034869 Plasma kallikrein Human genes 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- 102100021408 14-3-3 protein beta/alpha Human genes 0.000 claims 1
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 claims 1
- 102100024736 ATP-dependent RNA helicase DDX19B Human genes 0.000 claims 1
- 101710113909 ATP-dependent RNA helicase DDX19B Proteins 0.000 claims 1
- 101800004538 Bradykinin Proteins 0.000 claims 1
- 102400000967 Bradykinin Human genes 0.000 claims 1
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 claims 1
- 101710126270 Eukaryotic translation initiation factor 5A-1 Proteins 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 claims 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 1
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 claims 1
- 101710191011 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 claims 1
- QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 claims 1
- 108700023918 icatibant Proteins 0.000 claims 1
- 229960001062 icatibant Drugs 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017816A JP7412616B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
| JP2023218832A JP7693788B2 (ja) | 2016-09-16 | 2023-12-26 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
| JP2025094023A JP2025124852A (ja) | 2016-09-16 | 2025-06-05 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395712P | 2016-09-16 | 2016-09-16 | |
| US62/395,712 | 2016-09-16 | ||
| US201762518492P | 2017-06-12 | 2017-06-12 | |
| US62/518,492 | 2017-06-12 | ||
| PCT/US2017/051749 WO2018053244A1 (en) | 2016-09-16 | 2017-09-15 | Protein biomarkers for diseases associated with the contact activation system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017816A Division JP7412616B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529906A JP2019529906A (ja) | 2019-10-17 |
| JP2019529906A5 true JP2019529906A5 (cg-RX-API-DMAC7.html) | 2020-11-12 |
| JP7225089B2 JP7225089B2 (ja) | 2023-02-20 |
Family
ID=59974881
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514252A Active JP7225089B2 (ja) | 2016-09-16 | 2017-09-15 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
| JP2023017816A Active JP7412616B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
| JP2023218832A Active JP7693788B2 (ja) | 2016-09-16 | 2023-12-26 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
| JP2025094023A Pending JP2025124852A (ja) | 2016-09-16 | 2025-06-05 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017816A Active JP7412616B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
| JP2023218832A Active JP7693788B2 (ja) | 2016-09-16 | 2023-12-26 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
| JP2025094023A Pending JP2025124852A (ja) | 2016-09-16 | 2025-06-05 | 接触活性化系に関連する疾患のタンパク質バイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11815516B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3513196A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7225089B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102806918B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109716138B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017325983B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019005179A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3037154A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2019002599A2 (cg-RX-API-DMAC7.html) |
| IL (2) | IL265195B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019002932A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ792394A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018053244A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019005167A2 (pt) | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| CN113092769A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液补体c4-a及其多肽片段在过敏性疾病中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| ES2227545T3 (es) | 1994-01-11 | 2005-04-01 | Dyax Corporation | Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina. |
| US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| JP2001174463A (ja) | 1999-12-17 | 2001-06-29 | Hsp Research Institute Inc | 自己免疫疾患又は腫瘍の診断方法 |
| AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| DE60333758D1 (de) | 2002-06-07 | 2010-09-23 | Dyax Corp | Prevention und Verringerung von Ischemia |
| JP4399593B2 (ja) * | 2004-04-01 | 2010-01-20 | 国立大学法人 千葉大学 | インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| US8841259B2 (en) * | 2005-02-24 | 2014-09-23 | Joslin Diabetes Center | Compositions and methods for treating vascular permeability |
| GB2428240A (en) * | 2005-07-14 | 2007-01-24 | Univ Gen Ve | Diagnostic method for brain damage-related disorders |
| CA2630838A1 (en) | 2005-11-23 | 2007-05-31 | Georg Dewald | Detection and treatment of drug associated angioedema |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US20090104605A1 (en) * | 2006-12-14 | 2009-04-23 | Gary Siuzdak | Diagnosis of sepsis |
| AU2009285585A1 (en) * | 2008-08-28 | 2010-03-04 | Wyeth Llc | Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases |
| US8883153B2 (en) | 2009-03-27 | 2014-11-11 | The Research for The State University of New York | Methods for preventing and treating angioedema |
| SI3459564T1 (sl) | 2010-01-06 | 2022-06-30 | Takeda Pharmaceutical Company Limited | Proteini, ki vežejo plazemski kalikrein |
| US9102942B2 (en) | 2010-02-04 | 2015-08-11 | EWHA University—Industry Collaboration Foundation | Pharmaceutical composition for inhibiting abnormal proliferation of cells |
| JP2011226882A (ja) * | 2010-04-19 | 2011-11-10 | Kitasato Institute | 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット |
| JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| WO2012170947A2 (en) * | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| US20130102486A1 (en) * | 2011-10-20 | 2013-04-25 | The Board Of Trustees Of The Leland Stanford Junior University | Perp as a prognostic and diagnostic marker for dysplasia and cancer |
| EP3456744B1 (en) | 2013-01-20 | 2023-03-29 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| JP6656926B2 (ja) * | 2013-01-20 | 2020-03-04 | ダイアックス コーポレーション | ｐＫａｌ関連疾病の評価、アッセイおよび治療 |
| TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| AU2014340450B2 (en) * | 2013-10-21 | 2020-05-21 | Takeda Pharmaceutical Company Limited | Assays for determining plasma kallikrein system biomarkers |
| US10101344B2 (en) * | 2013-10-21 | 2018-10-16 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| EA038532B1 (ru) * | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| CA2940585C (en) * | 2014-04-15 | 2023-08-08 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Differential diagnosis of eczema and psoriasis |
| BR112019005167A2 (pt) | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| IL315175A (en) | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | RNA biomarkers for hereditary angioedema |
-
2017
- 2017-09-15 IL IL265195A patent/IL265195B2/en unknown
- 2017-09-15 CN CN201780057056.2A patent/CN109716138B/zh active Active
- 2017-09-15 CA CA3037154A patent/CA3037154A1/en active Pending
- 2017-09-15 KR KR1020237009552A patent/KR102806918B1/ko active Active
- 2017-09-15 US US16/333,155 patent/US11815516B2/en active Active
- 2017-09-15 MX MX2019002932A patent/MX2019002932A/es unknown
- 2017-09-15 KR KR1020257015097A patent/KR20250073510A/ko active Pending
- 2017-09-15 KR KR1020197010801A patent/KR102513485B1/ko active Active
- 2017-09-15 WO PCT/US2017/051749 patent/WO2018053244A1/en not_active Ceased
- 2017-09-15 NZ NZ792394A patent/NZ792394A/en unknown
- 2017-09-15 AU AU2017325983A patent/AU2017325983B2/en active Active
- 2017-09-15 BR BR112019005179A patent/BR112019005179A2/pt unknown
- 2017-09-15 JP JP2019514252A patent/JP7225089B2/ja active Active
- 2017-09-15 CN CN202311187493.XA patent/CN117192130A/zh active Pending
- 2017-09-15 EP EP17777136.7A patent/EP3513196A1/en active Pending
- 2017-09-15 IL IL315799A patent/IL315799A/en unknown
-
2019
- 2019-03-13 MX MX2024009782A patent/MX2024009782A/es unknown
- 2019-03-21 CO CONC2019/0002599A patent/CO2019002599A2/es unknown
-
2023
- 2023-02-08 JP JP2023017816A patent/JP7412616B2/ja active Active
- 2023-10-04 US US18/480,709 patent/US20240142468A1/en active Pending
- 2023-12-26 JP JP2023218832A patent/JP7693788B2/ja active Active
-
2024
- 2024-03-07 AU AU2024201506A patent/AU2024201506B2/en active Active
-
2025
- 2025-06-05 JP JP2025094023A patent/JP2025124852A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Freue et al. | Proteomic signatures in plasma during early acute renal allograft rejection | |
| CN105073778B (zh) | 缓激肽介导的病症的评估和治疗 | |
| JP2011209291A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Allergen challenge of peripheral blood mononuclear cells from patients with seasonal allergic rhinitis increases IL‐17RB, which regulates basophil apoptosis and degranulation | |
| Franciosi et al. | Susceptibility to COPD: differential proteomic profiling after acute smoking | |
| JP2016511394A (ja) | ｐＫａｌ関連疾病の評価、アッセイおよび治療 | |
| JP2015530868A5 (cg-RX-API-DMAC7.html) | ||
| KR20220158231A (ko) | 무세포 뉴클레오솜 수준을 사용한 분류 방법 | |
| JP2017500584A5 (cg-RX-API-DMAC7.html) | ||
| Hirschbühl et al. | High viral loads: what drives fatal cases of COVID-19 in vaccinees?–an autopsy study | |
| JP2023058608A5 (cg-RX-API-DMAC7.html) | ||
| Bolayır et al. | The role of SCUBE1 in the pathogenesis of no-reflow phenomenon presenting with ST segment elevation myocardial infarction | |
| JP2019529906A5 (cg-RX-API-DMAC7.html) | ||
| JP6046053B2 (ja) | Ｂｃｌ−２様タンパク質１１のＳＲＭ／ＭＲＭアッセイ | |
| Bennike | Advances in proteomics: characterization of the innate immune system after birth and during inflammation | |
| CN106170700A (zh) | 用于狼疮肾炎的治疗性随访中的预测、诊断和监测的体外方法 | |
| KR20140002150A (ko) | 췌장암 재발 예후 예측용 마커 및 이의 용도 | |
| EP3044594A1 (en) | Identification of novel biomarkers of flares of systemic lupus erythematosus | |
| ES2846836T3 (es) | Método para predecir la sensibilidad a una terapia combinada con lenvatinib y everolimus | |
| US9029094B2 (en) | Biomechanical-based methods of diagnosing scoliosis | |
| ES2939143T3 (es) | Biomarcadores para una politerapia que comprende lenvatinib y everolimus | |
| An et al. | Dynamic and reversible transcriptomic age shifts induced by COVID-19 in Korean whole blood | |
| KR20210005100A (ko) | 선택된 환자에서 심혈관 질환을 치료하기 위한 조성물 및 방법 | |
| CN105203770B (zh) | Stim1蛋白在相关疾病风险诊断中的应用 | |
| CN111426835A (zh) | 肝转移癌相关的尿液蛋白标记物的筛选及其用途 |